Published in Drug Metab Dispos on November 05, 2012
The effect of the neonatal Fc receptor on human IgG biodistribution in mice. MAbs (2014) 0.84
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. CPT Pharmacometrics Syst Pharmacol (2015) 0.83
Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. AAPS J (2014) 0.76
Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res (2014) 0.75
A drug burden index to define the functional burden of medications in older people. Arch Intern Med (2007) 2.84
Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care (2010) 1.60
Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos (2004) 1.56
Merging systems biology with pharmacodynamics. Sci Transl Med (2012) 1.39
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn (2009) 1.33
Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci (2008) 1.21
Drug burden index score and functional decline in older people. Am J Med (2009) 1.19
Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol (2012) 1.06
Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome. Pain Physician (2010) 1.05
Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther (2008) 1.05
Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res (2011) 1.04
Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J (2007) 1.03
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res (2010) 1.01
Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res (2005) 1.01
Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther (2004) 0.96
Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans. J Pharmacol Exp Ther (2009) 0.96
Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab Dispos (2004) 0.95
Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant (2013) 0.92
Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn (2009) 0.91
Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J (2009) 0.90
Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol (2009) 0.89
Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Res (2012) 0.89
Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res (2012) 0.89
Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome. Chirality (2010) 0.88
Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation. Pharm Res (2012) 0.87
Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol (2008) 0.86
A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. J Clin Pharmacol (2011) 0.86
Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet (2008) 0.84
Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharm Drug Dispos (2011) 0.83
Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci (2003) 0.83
Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status. Drug Metab Dispos (2013) 0.82
Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol (2008) 0.82
Identification of plasma membrane macro- and microdomains from wavelet analysis of FRET microscopy. Biophys J (2005) 0.82
Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability. Pharm Res (2007) 0.82
HPLC-atmospheric pressure chemical ionization mass spectrometric method for enantioselective determination of R,S-propranolol and R,S-hyoscyamine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.82
Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res (2012) 0.81
Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J Pharmacol Exp Ther (2012) 0.81
Quantitative structure-pharmacokinetic relationships. Expert Opin Drug Metab Toxicol (2010) 0.81
Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition. Pharm Res (2013) 0.81
Pharmacokinetics and toxicodynamics of pralidoxime effects on paraoxon-induced respiratory toxicity. Toxicol Sci (2010) 0.80
Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. J Pharmacokinet Pharmacodyn (2015) 0.80
Quantitative structure–property relationships of camptothecins in humans. Cancer Chemother Pharmacol (2010) 0.80
Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharm Drug Dispos (2014) 0.79
Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice. J Pharmacol Exp Ther (2010) 0.79
Mechanism-based pharmacodynamic modeling. Methods Mol Biol (2012) 0.79
Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. J Pharm Sci (2014) 0.79
Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. J Pharm Sci (2013) 0.79
Pharmacodynamic model of parathyroid hormone modulation by a negative allosteric modulator of the calcium-sensing receptor. AAPS J (2011) 0.78
Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. J Pharm Sci (2003) 0.78
Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. Biopharm Drug Dispos (2014) 0.78
Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. J Pharm Sci (2013) 0.78
Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metab Dispos (2010) 0.77
Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis. Biopharm Drug Dispos (2013) 0.77
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. Cancer Chemother Pharmacol (2014) 0.77
Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. Biopharm Drug Dispos (2013) 0.76
Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. Cancer Chemother Pharmacol (2015) 0.76
Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2010) 0.76
Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice. Pharm Res (2012) 0.75
Bridging pharmacology and pathophysiology via systems modeling. J Clin Pharmacol (2010) 0.75
Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res (2014) 0.75
Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates. Drug Deliv (2010) 0.75
Population pharmacodynamic modeling of hyperglycemic clamp and meal tolerance tests in patients with type 2 diabetes mellitus. AAPS J (2013) 0.75
Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. J Pharmacol Exp Ther (2009) 0.75
Population pharmacokinetic model for a novel oral hypoglycemic formed in vivo: comparing the use of active metabolite data alone versus using data of upstream and downstream metabolites. J Clin Pharmacol (2011) 0.75
Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol). J Clin Pharmacol (2009) 0.75
Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clin Pharmacol Ther (2004) 0.75
Population-based meta-analysis of furosemide pharmacokinetics. Biopharm Drug Dispos (2013) 0.75